Skip to main content

4 Result(s)

within Medicine & Public Health Remove this filter Pathology Remove this filter Hiroaki Sakamoto Remove this filter

and

  1. No Access

    Article

    A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations

    We report a case of 2-year-old female with lateral ventricular glioma harboring both H3F3A K27M and BRAF V600E mutations. By the methylation analysis, the tumor was classified as a diffuse midline glioma H3 K27M ...

    Yoshiko Nakano, Kai Yamasaki, Hiroaki Sakamoto, Yasuhiro Matsusaka… in Brain Tumor Pathology (2019)

  2. Article

    Open Access

    Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer

    Afatinib, a second-generation epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC), was approved in Japan in 2014. This study evaluated clinical...

    Hisashi Tanaka, Kageaki Taima, Masamichi Itoga, Yoshiko Ishioka… in Medical Oncology (2019)

    Download PDF (1007 KB) View Article

  3. No Access

    Article

    Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome

    We focused on histological and immunohistochemical characteristics of ependymoma (EPN) with molecular profiles to develop more reproducible criteria of the diagnosis. Three expert neuropathologists reviewed th...

    Atsushi Sasaki, Junko Hirato, Takanori Hirose, Kohei Fukuoka… in Brain Tumor Pathology (2019)

  4. No Access

    Article

    Identification of a novel KLC1–ROS1 fusion in a case of pediatric low-grade localized glioma

    The proto-oncogene tyrosine-protein kinase ROS1 (ROS1) is a tyrosine kinase that is closely related to anaplastic lymphoma kinase receptor (ALK). We describe a novel KLC1–ROS1 fusion identified in a case of pedia...

    Yoshiko Nakano, Arata Tomiyama, Takashi Kohno, Akihiko Yoshida… in Brain Tumor Pathology (2019)